Pharmaceutical Firm Exceeds Expectations DPHARMA: Pharmaceutical Firm Exceeds Expectations on Robust Sales and Margin Growth Investment Bank TA SECURITIES TP (Target Price) RM0.25 (+25.0%) Last Traded RM0.20 Recommendation BUY A prominent pharmaceutical company reported core earnings for the first nine months of 2025 that were well within market expectations, driven by strong public sector sales…
“`html Investment Report Analysis DPHARMA: Earnings Surpass Expectations Driven by Cost Controls, Positive Outlook Affirmed Investment Bank TA SECURITIES TP (Target Price) RM0.25 (+25.0%) Last Traded RM0.20 Recommendation BUY The company reported a solid financial performance for the nine months ended 9M25, with net profit aligning with both internal and consensus expectations. The robust results…
Duopharma Biotech: Strong Performance and Positive Outlook RHB Small Cap Asean Research 22 August 2025 Duopharma Biotech (DBB MK): Strong Performance and Positive Outlook On a Solid Footing; Maintain BUY Shariah Compliant Malaysia Results Review Consumer Non-cyclical | Pharmaceuticals Keep BUY and DCF-derived MYR1.56 TP, 18% upside and c.2% FY25F yield. Duopharma Biotech booked 2Q25…
Duopharma Biotech’s Q2 2025 Report: Strong Profit Growth and a Dividend Boost for Shareholders Duopharma Biotech Berhad, a leading name in Malaysia’s pharmaceutical industry, has just released its financial results for the second quarter ending June 30, 2025. The report reveals a story of robust profit growth and strengthening financial health, culminating in a higher…
